EU MDR Summary of Safety and Clinical Performance (SSCP): Complete Guide for Class III and Implantable Devices

The SSCP Is the Most Scrutinised Public-Facing Document Under EU MDR

The Summary of Safety and Clinical Performance (SSCP) is a mandatory regulatory document introduced by Article 32 of the EU Medical Device Regulation (MDR 2017/745). It applies to all Class III devices and all implantable devices, excluding custom-made and investigational devices. Unlike the technical file — which stays between the manufacturer and the Notified Body — the SSCP is validated by the Notified Body and then published in EUDAMED for public access by healthcare professionals and patients.

This transparency mechanism is one of the defining features of the MDR compared to the former Medical Device Directive (MDD). As of May 28, 2026, when EUDAMED becomes mandatory for device registration, all SSCPs for CE-marked Class III and implantable devices must be uploaded and publicly accessible.

This guide covers the complete SSCP lifecycle: from understanding the MDCG 2019-9 Rev.1 template structure, through drafting both the healthcare professional and layperson sections, to Notified Body validation, translation, and ongoing maintenance.

Who Needs an SSCP?

The SSCP requirement applies to:

For Class III and most Class IIb implantable devices, the draft SSCP must be submitted as part of the conformity assessment application documents and validated by the Notified Body before the certificate is issued. For Class IIa implantable devices such as sutures and staples, a draft SSCP must also be submitted and validated.

MDCG 2019-9 Rev.1: The Definitive Guidance

The primary guidance document for SSCP preparation is MDCG 2019-9 Rev.1, published by the Medical Device Coordination Group. The original version was released in August 2019, and Revision 1 was published in March 2022 with key clarifications:

• Section 3.1: Clarification on the association of the SSCP with the Basic UDI-DI in EUDAMED and the addition of the manufacturer's reference number in the general requirements and template.
• The revision reinforced that the SSCP must be objective and adequately summarise both favourable and unfavourable data.
• The recommended template structure was refined to enhance presentation and readability.

All manufacturers should use the MDCG 2019-9 Rev.1 template as the starting point for their SSCP. While the format is recommended rather than mandatory, deviating from it increases the risk of Notified Body queries and delays.

SSCP Structure: The 9 Required Sections

The MDCG 2019-9 Rev.1 template defines the following sections for the healthcare professional (HCP) SSCP:

Section 1: Device Identification and General Information

This section provides the administrative identity of the device. Required elements include:

• Device trade name and manufacturer name
• Basic UDI-DI (as referred to in Part C of Annex VI)
• Manufacturer's Single Registration Number (SRN)
• Notified Body identification number
• Risk class and applicable classification rule(s)
• Year of first CE marking and, if applicable, year of first placing on the EU market under the MDD/AIMDD
• Whether the device is an implantable device

Section 2: Intended Use of the Device

This covers the clinical purpose and context of use:

• Intended purpose: What the device is designed to do
• Indications for use: The clinical conditions, patient populations, and scenarios for which the device is intended
• Contraindications: Conditions or patient groups where the device should not be used
• Target patient population: Demographics, disease characteristics, and selection criteria
• Intended user profile: Qualifications and training required to use the device safely

The information must be consistent with the Instructions for Use (IFU) and the clinical evaluation report.

Section 3: Device Description

A technical description that enables healthcare professionals to understand what the device is, how it works, and what it is made of:

• Physical design and principle of operation
• Key materials in contact with the patient
• Accessories and combination devices
• If applicable, a description of any medicinal substance, human blood or plasma derivative, or animal tissue
• If applicable, information on the device's electronic or software components

Section 4: Risks and Warnings

This section must present an objective summary of residual risks, undesirable effects, and warnings:

• Residual risks: Risks remaining after risk control measures have been applied (per ISO 14971:2019)
• Undesirable effects: Known side effects and adverse events, with frequency where available
• Warnings and precautions: Safety information from the IFU
• Other relevant safety information: Field Safety Corrective Actions (FSCAs) if applicable

The SSCP must present both favourable and unfavourable data. Selective omission of known adverse events or secondary endpoint failures will be flagged as incomplete or misleading by the Notified Body, who has access to the full clinical evaluation report.

Section 5: Summary of Clinical Evaluation and PMCF

This is typically the most substantive section. It must include:

• Summary of clinical evaluation: An overview of the clinical data, including clinical investigations, post-market surveillance data, and relevant scientific literature
• Clinical benefit: The positive impact on patient health, with supporting evidence
• Clinical safety: A summary of safety outcomes from clinical data
• PMCF activities: The nature of PMCF activities, what they are designed to investigate, and key findings to date

A common Notified Body finding is a generic PMCF statement such as "PMCF activities are ongoing in accordance with the PMCF Plan." MDCG 2019-9 requires the SSCP to specify the nature of PMCF activities and report key findings.

The benefit-risk conclusion must be clear, evidence-based, and reference the state of the art for the indication.

Section 6: Possible Diagnostic or Therapeutic Alternatives

Describe other management options for the same condition, including:

• Alternative device-based treatments
• Pharmacological alternatives
• Non-interventional management ("watchful waiting")
• The risks and benefits of each alternative

This section helps healthcare professionals make informed treatment decisions by contextualising the device within the broader clinical landscape.

Section 7: Suggested Profile and Training for Users

Describe the experience, education, and training required for safe use:

• Minimum qualifications for the intended user
• Any mandatory training programmes before first use
• Update or refresher training for continued safe use
• Whether training is provided by the manufacturer or through recognised specialty bodies

Section 8: Reference to Harmonised Standards and Common Specifications

List all harmonised standards and common specifications applied during the conformity assessment. This provides traceability between the SSCP and the technical documentation. As of January 2026, the latest update to harmonised standards under MDR was published via Implementing Decision (EU) 2026/193, which added several revised standards including EN ISO 10993-4:2017/A1:2025 for biological evaluation of blood interactions and EN ISO 17665:2024 for sterilisation.

The Layperson SSCP Section

In addition to the HCP section, devices intended for use by laypersons or devices that are normally accompanied by an implant card must include a separate layperson section written in plain language.

Key Requirements for the Layperson Section

The layperson section is not an abbreviated version of the HCP section. It requires active rewriting in plain language. Copying and shortening the technical section while keeping medical terminology, statistical language, and acronyms will result in a Notified Body query.

Readability Testing Methods

MDCG 2019-9 recommends confirming readability through one or more of the following:

• Flesch-Kincaid Grade Level test: Measures the U.S. school grade level required to understand the text
• Flesch Reading Ease score: Higher scores indicate easier readability
• Gunning Fog Index: Estimates the years of formal education needed
• Layperson review: Having non-medical individuals read and confirm comprehension
• Patient advocacy group review: Some manufacturers engage patient organisations for feedback

SSCP Validation by the Notified Body

The SSCP must be validated by the Notified Body. The timing of validation depends on the device class and conformity assessment route:

What the Notified Body Checks

Notified Bodies evaluate the SSCP for:

1. Consistency: SSCP content must align with the CER, IFU, risk management file, and PSUR
2. Completeness: All required sections must be present and substantively addressed
3. Objectivity: Both favourable and unfavourable data must be presented
4. Readability: The layperson section must demonstrate appropriate plain language
5. Non-promotional language: The SSCP must not contain any promotional claims
6. Accuracy of translations: While the NB validates the English "master" SSCP, translations into other EU languages are not validated by the NB

Common Notified Body Findings (2025-2026)

Based on NB audit data and industry reports, these are the most frequent SSCP issues:

Translation Requirements

The SSCP follows MDR language requirements similar to other technical documents:

• English master version: Required for all devices. The NB validates the English version.
• Other EU languages: Must be translated into the official languages of the Member States where the device is sold. The European Commission published Revision 3 (August 2025) of its consolidated overview of national language requirements under MDR.
• Translation timing: The manufacturer must provide translations to the NB within 90 days of uploading the "master" SSCP. The NB uploads the English translation within 15 days of receiving it. Translations into other languages are uploaded within 15 days of receipt.
• NB validation scope: The NB does not validate translated SSCP documents. The manufacturer is responsible for ensuring translation accuracy through their quality management system.
• Language statement: The SSCP must clearly state in which language it was validated by the Notified Body.

EUDAMED Upload and Publication Timeline

With EUDAMED's first four modules declared fully functional on November 27, 2025, the following timeline applies:

For the SSCP specifically:

• The NB is responsible for uploading the validated SSCP into EUDAMED
• Before EUDAMED becomes mandatory, manufacturers must make the SSCP available upon request
• The IFU must contain all information needed to directly find the SSCP in EUDAMED

SSCP Maintenance and Update Triggers

The SSCP is a living document that must be continuously updated throughout the device lifecycle. Update triggers include:

• PSUR updates: For Class III devices and Class IIb implantable devices (both requiring annual PSURs), the SSCP should be reviewed and updated in alignment with PSUR cycles
• New clinical data: Any significant new clinical findings from PMCF activities or published literature
• Field Safety Corrective Actions: FSCAs must be reflected in the risks and warnings section
• CER updates: When the clinical evaluation report is updated, the SSCP must be reviewed for consistency
• IFU changes: Any changes to indications, contraindications, or warnings in the IFU must be reflected in the SSCP

The updated SSCP must be re-validated by the Notified Body before being uploaded to EUDAMED.

SSCP vs. Other MDR Documents: Comparison Table

Step-by-Step SSCP Preparation Workflow

Step 1: Establish Templates

Create two templates aligned with MDCG 2019-9 Rev.1: one for the HCP section and one for the layperson section. Ensure template version control within your QMS.

Step 2: Gather Source Data

Pull information from:

• Clinical Evaluation Report (CER)
• Risk Management File (ISO 14971:2019)
• Instructions for Use (IFU)
• Post-Market Surveillance Plan and Reports
• PMCF Plan and Reports
• PSUR (if available)

Step 3: Draft the HCP Section

Write each section following the MDCG 2019-9 template. Ensure:

• Clinical data is presented objectively, including both favourable and unfavourable findings
• Residual risks are quantified where possible (frequency categories)
• PMCF activities are described specifically, not generically
• All data is sourced from the technical documentation

Step 4: Draft the Layperson Section

Rewrite key information in plain language:

• Replace medical terms with everyday language (e.g., "myocardial infarction" → "heart attack")
• Use short sentences and simple sentence structure
• Include the recommendation to discuss alternatives with a healthcare professional
• Run readability testing (Flesch-Kincaid, Gunning Fog, or layperson review)

Step 5: Internal Review

Have the SSCP reviewed by:

• Regulatory Affairs team for compliance with Article 32 and MDCG 2019-9
• Clinical team for accuracy of clinical data presentation
• Legal or claims management team for non-promotional language
• Quality team for consistency with QMS documentation

Step 6: Notified Body Submission

Submit the draft SSCP as part of your conformity assessment application. Address any NB queries or findings before certificate issuance.

Step 7: Translation

Translate the validated English "master" SSCP into all required EU languages. Ensure translations are accurate and maintain readability in each target language.

Step 8: EUDAMED Publication

The NB uploads the validated SSCP to EUDAMED. Ensure the IFU references where to find the SSCP.

Step 9: Ongoing Maintenance

Establish a schedule for SSCP review aligned with your PSUR cycle and PMCF reporting. Document the review process in your QMS.

SSCP Readability Comparison: HCP vs. Layperson Sections

FAQ

Q: Do custom-made devices require an SSCP? No. Article 32(1) explicitly excludes custom-made and investigational devices from the SSCP requirement.

Q: When should the SSCP first be submitted? For Class III and Class IIb implantable devices (excluding sutures and staples), the draft SSCP must be submitted as part of the conformity assessment application documents, before the Notified Body issues the certificate.

Q: Who uploads the SSCP to EUDAMED? The Notified Body is responsible for uploading the validated SSCP to EUDAMED. The manufacturer provides the SSCP and translations to the NB.

Q: Does the NB validate all language versions? No. The NB validates only the English "master" SSCP. Translations into other EU languages are the manufacturer's responsibility and are not separately validated by the NB.

Q: How often must the SSCP be updated? The SSCP must be continuously updated. At minimum, it should be reviewed each time the PSUR is updated (annually for Class III, every two years for Class IIb implantable). Significant new clinical data, FSCAs, or IFU changes also trigger an update.

Q: What happens if the SSCP is inconsistent with the CER? This is one of the most common and most serious Notified Body findings. An inconsistent SSCP signals a quality management failure and can generate a critical non-conformity. Manufacturers must implement a process to ensure the SSCP is reviewed whenever the CER, PSUR, or IFU is updated.

Q: Is the SSCP required for Class IIa non-implantable devices? No. The SSCP requirement applies only to Class III devices and implantable devices across all applicable classes.

Q: Can the layperson section be an abbreviated version of the HCP section? No. The layperson section must be actively rewritten in plain language. Copying and shortening the HCP section while retaining technical terminology is a routine formal query at all major Notified Bodies.

Q: What readability level should the layperson section target? MDCG 2019-9 recommends readability at a U.S. Grade 8 level (approximately 12-14 years of age). Use validated readability tests such as Flesch-Kincaid or Gunning Fog to confirm.

Q: Does the December 2025 MDR simplification proposal affect SSCP requirements? As of April 2026, the MDR/IVDR simplification proposal published in December 2025 is still under legislative review. The SSCP requirements under Article 32 remain unchanged. Manufacturers should continue to comply with current requirements while monitoring legislative developments.

Key Takeaways

The SSCP is a transparency tool unique to EU MDR that places clinical evidence for high-risk devices into the public domain. Success requires rigorous alignment between the SSCP, CER, IFU, risk management file, and PSUR — enforced through a structured QMS process. The most common pitfalls — inconsistency with the CER, inadequate layperson readability, and generic PMCF content — are entirely preventable with proper template management and review cycles. With EUDAMED mandatory from May 28, 2026, manufacturers who have not yet prepared their SSCPs should prioritise this as an immediate compliance action.